Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 24, 2023 18:15 ET | Source: MacroGenics, Inc.

MacroGenics to Participate in Upcoming Investor Conferences

ROCKVILLE, MD, April 24, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for...
March 22, 2023 13:22 ET | Source: MacroGenics, Inc.

MacroGenics Earns $15 Million Milestone Following U.S. FDA Approval of ZYNYZ™ (retifanlimab-dlwr)

ROCKVILLE, MD, March 22, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for...
March 15, 2023 16:01 ET | Source: MacroGenics, Inc.

MacroGenics Provides Corporate Update and 2022 Financial Results

Cash runway extended through 2025 with $250 million in non-dilutive funding over past eight months TAMARACK study design modified with objective of accelerating data readoutEncouraging lorigerlimab...
March 08, 2023 17:36 ET | Source: MacroGenics, Inc.

MacroGenics Announces Sale of TZIELD™ Royalty Interest for up to $200 Million

ROCKVILLE, MD, March 08, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
March 07, 2023 18:00 ET | Source: MacroGenics, Inc.

MacroGenics Announces Date of Fourth Quarter 2022 Financial Results Conference Call

ROCKVILLE, MD, March 07, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
March 02, 2023 16:30 ET | Source: MacroGenics, Inc.

MacroGenics to Participate in Upcoming Investor Conferences

ROCKVILLE, MD, March 02, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for...
February 13, 2023 17:20 ET | Source: MacroGenics, Inc.

MacroGenics Announces Preliminary Clinical Results from Single Arm Study of Lorigerlimab in Patients with Metastatic Castration-Resistant Prostate Cancer to be Presented at ASCO Genitourinary Cancers Symposium

Twelve of 42 patients (28.6%) in metastatic castration-resistant prostate cancer (mCRPC) cohort achieved ≥ 50% prostate-specific antigen (PSA) reduction (PSA50), including 9 (21.4%) who achieved ≥ 90%...
February 06, 2023 16:30 ET | Source: MacroGenics, Inc.

MacroGenics to Participate in Upcoming Investor Conferences

ROCKVILLE, MD, Feb. 06, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for...
January 04, 2023 17:50 ET | Source: MacroGenics, Inc.

MacroGenics to Present at the 41st Annual J.P. Morgan Healthcare Conference

ROCKVILLE, MD, Jan. 04, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics...
January 04, 2023 16:30 ET | Source: MacroGenics, Inc.

MacroGenics Announces Appointment of Dr. Margaret Liu and Meenu Chhabra Karson to Board of Directors

ROCKVILLE, MD, Jan. 04, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for...